Oxford Biotherapeutics Ltd

Medarex Inc.

E. R. Squibb Sons, Inc.

Erika Meaddough

Haichun Huang

Jonathan Alexander Terrett

Chin Pan

Chetana Rao-Naik

Heidi N Leblanc

Sarah Lee Pogue

Bingliang Chen

Michelle Renee Kuhne

The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.

Antibodies

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.

Fully human antibodies specific to CADM1

Growing community of inventors

Gilroy, CA, United States of America

Erika Meaddough